GANX250117C4000
- 0.00
- 0.000.00%
Gain Therapeutics Newsroom
Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study
Express News | Gain Therapeutics Inc - Enrollment Expected to Complete in Spring 2025, Data Expected Mid-2025
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People With GBA1 and Idiopathic Parkinson's Disease
Express News | Gain Therapeutics Initiates Phase 1B Clinical Trial of Lead Candidate GT-02287 in People With Gba1 and Idiopathic Parkinson’s Disease
Gain Therapeutics To Present At Biotech Showcase 2025
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $7
Gain Therapeutics Price Target Announced at $7.00/Share by Roth MKM
Gain Therapeutics Initiated at Buy by Roth MKM
Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Gain Therapeutics Advances Parkinson's Therapy Development
Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease
Gain Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
Gain Therapeutics | 8-K: Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics Q3 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate
Gain Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics Shares Are Trading Higher After the Company Announced He Presentation of a Poster That Details the Use of Its Magellan Drug Discovery Platform to Identify Allosteric Inhibitors Targeting Discoidin Domain Receptor 2.
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics